Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss (NCT06810544)

🧪 Interventions in This Study

• TNG456 (DRUG)
• abemaciclib (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Has a tumor with a confirmed MTAP loss
2. Is ≥18 years of age at the time of signature of the main study ICF
3. Has had progression or an inadequate response to or is intolerant of the approved standard of care therapy, no standard of care therapy exists, or the investigator has determined that treatment with the standard of care therapy is not appropriate.
4. Is able to swallow tablets
5. Adequate Organ function/reserve per local labs
6. Negative serum pregnancy test result at screening
7. Has an ECOG performance status score of 0 to 1
8. Has measurable disease based on RECIST v1.1 or a confirmed glioblastoma (IDH-wildtype) with radiographic evidence of disease progression or recurrence defined by RANO 2.0.
9. Has an ECOG performance score of 0 to 1 or for GBM has a Karnofsky performance status score ≥70.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (15 Sites)

• Mayo Clinic Scottsdale — Scottsdale, Arizona
• University of California, Irvine — Irvine, California
• University of California Los Angeles — Los Angeles, California
• University of California at San Francisco — San Francisco, California
• Sibley Memorial Hospital — Washington D.C., District of Columbia
• Mayo Clinic Jacksonville — Jacksonville, Florida
• Northwestern Memorial Hospital — Chicago, Illinois
• Dana Farber Cancer Institute — Boston, Massachusetts
• Mayo Clinic Cancer Center — Rochester, Minnesota
• NYU Langone Health — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• Ohio State University Comprehensive Cancer Center — Columbus, Ohio
• MD Anderson Cancer Center — Houston, Texas
• University of Utah, Huntsman Cancer Institute — Salt Lake City, Utah
• NEXT Virginia — Fairfax, Virginia

📞 Contact the Study Coordinator

Phone: (857) 320-4899

Email: clinicaltrials@tangotx.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non Small Cell Lung Cancer

• Using ctDNA to Determine Therapies for Lung Cancer — Toronto, Ontario
• Biology of Young Lung Cancer Study: The YOUNG LUNG Study — Boston, Massachusetts
• Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC — Pittsburgh, Pennsylvania
• Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X) — Milwaukee, Wisconsin
• The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance — Boston, Massachusetts

Explore by condition: All Non Small Cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.